Cargando…
Evolving Antibiotics against Resistance: a Potential Platform for Natural Product Development?
To avoid an antibiotic resistance crisis, we need to develop antibiotics at a pace that matches the rate of evolution of resistance. However, the complex functions performed by antibiotics—combining, e.g., penetration of membranes, counteraction of resistance mechanisms, and interaction with molecul...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6935861/ https://www.ncbi.nlm.nih.gov/pubmed/31874919 http://dx.doi.org/10.1128/mBio.02946-19 |
_version_ | 1783483648544079872 |
---|---|
author | Wollein Waldetoft, Kristofer Gurney, James Lachance, Joseph Hoskisson, Paul A. Brown, Sam P. |
author_facet | Wollein Waldetoft, Kristofer Gurney, James Lachance, Joseph Hoskisson, Paul A. Brown, Sam P. |
author_sort | Wollein Waldetoft, Kristofer |
collection | PubMed |
description | To avoid an antibiotic resistance crisis, we need to develop antibiotics at a pace that matches the rate of evolution of resistance. However, the complex functions performed by antibiotics—combining, e.g., penetration of membranes, counteraction of resistance mechanisms, and interaction with molecular targets—have proven hard to achieve with current methods for drug development, including target-based screening and rational design. Here, we argue that we can meet the evolution of resistance in the clinic with evolution of antibiotics in the laboratory. On the basis of the results of experimental evolution studies of microbes in general and antibiotic production in Actinobacteria in particular, we propose methodology for evolving antibiotics to circumvent mechanisms of resistance. This exploits the ability of evolution to find solutions to complex problems without a need for design. We review evolutionary theory critical to this approach and argue that it is feasible and has important advantages over current methods for antibiotic discovery. |
format | Online Article Text |
id | pubmed-6935861 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | American Society for Microbiology |
record_format | MEDLINE/PubMed |
spelling | pubmed-69358612020-01-03 Evolving Antibiotics against Resistance: a Potential Platform for Natural Product Development? Wollein Waldetoft, Kristofer Gurney, James Lachance, Joseph Hoskisson, Paul A. Brown, Sam P. mBio Opinion/Hypothesis To avoid an antibiotic resistance crisis, we need to develop antibiotics at a pace that matches the rate of evolution of resistance. However, the complex functions performed by antibiotics—combining, e.g., penetration of membranes, counteraction of resistance mechanisms, and interaction with molecular targets—have proven hard to achieve with current methods for drug development, including target-based screening and rational design. Here, we argue that we can meet the evolution of resistance in the clinic with evolution of antibiotics in the laboratory. On the basis of the results of experimental evolution studies of microbes in general and antibiotic production in Actinobacteria in particular, we propose methodology for evolving antibiotics to circumvent mechanisms of resistance. This exploits the ability of evolution to find solutions to complex problems without a need for design. We review evolutionary theory critical to this approach and argue that it is feasible and has important advantages over current methods for antibiotic discovery. American Society for Microbiology 2019-12-24 /pmc/articles/PMC6935861/ /pubmed/31874919 http://dx.doi.org/10.1128/mBio.02946-19 Text en Copyright © 2019 Wollein Waldetoft et al. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Opinion/Hypothesis Wollein Waldetoft, Kristofer Gurney, James Lachance, Joseph Hoskisson, Paul A. Brown, Sam P. Evolving Antibiotics against Resistance: a Potential Platform for Natural Product Development? |
title | Evolving Antibiotics against Resistance: a Potential Platform for Natural Product Development? |
title_full | Evolving Antibiotics against Resistance: a Potential Platform for Natural Product Development? |
title_fullStr | Evolving Antibiotics against Resistance: a Potential Platform for Natural Product Development? |
title_full_unstemmed | Evolving Antibiotics against Resistance: a Potential Platform for Natural Product Development? |
title_short | Evolving Antibiotics against Resistance: a Potential Platform for Natural Product Development? |
title_sort | evolving antibiotics against resistance: a potential platform for natural product development? |
topic | Opinion/Hypothesis |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6935861/ https://www.ncbi.nlm.nih.gov/pubmed/31874919 http://dx.doi.org/10.1128/mBio.02946-19 |
work_keys_str_mv | AT wolleinwaldetoftkristofer evolvingantibioticsagainstresistanceapotentialplatformfornaturalproductdevelopment AT gurneyjames evolvingantibioticsagainstresistanceapotentialplatformfornaturalproductdevelopment AT lachancejoseph evolvingantibioticsagainstresistanceapotentialplatformfornaturalproductdevelopment AT hoskissonpaula evolvingantibioticsagainstresistanceapotentialplatformfornaturalproductdevelopment AT brownsamp evolvingantibioticsagainstresistanceapotentialplatformfornaturalproductdevelopment |